Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma.
CEA cell adhesion molecule 6 and surfactant protein B
exosomes
keratin 5
lung adenocarcinoma
lung squamous cell carcinoma
tumor protein P63
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
21
08
2020
accepted:
08
01
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
ppublish
Résumé
The determination of biomarkers in the blood specific for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) is crucial for the selection of effective treatment strategies and the prediction of prognosis. The purpose of the present study was to analyze the differentially expressed genes (DEGs) in LUSC and LUAD from The Cancer Genome Atlas (TCGA) database. In order to identify the potential biomarkers for non-small cell lung cancer (NSCLC) for clinical diagnosis, bioinformatics was used to analyze the DEGs of two subtypes of NSCLC, LUAD and LUSC. Exosomes were isolated from the serum of patients with LUAD or LUSC and identified using transmission electron microscopy, nanoparticle tracking analysis and western blot analysis. A total of four differential exosomal mRNAs were selected for validation with serum samples from 70 patients with NSCLC via reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic curves were established to evaluate the clinical diagnostic value of four DEGs for patients with LUAD and LUSC. The analysis based on TCGA data revealed the DEGs in LUSC and LUAD: A total of 1,619 genes were differentially expressed in patients with LUSC and LUAD. DEGs analyzed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses revealed that inflammation-related signaling pathways, such as complement pathways, and multiple autoimmune diseases, such as systemic lupus erythematosus and asthma were mainly enriched in LUAD. The cell cycle, Hippo signaling pathway, Rap1 signaling pathway and Wnt signaling pathway were the main signaling pathways enriched in LUSC. The combination of tumor protein P63 (TP63), keratin 5 (KRT5), CEA cell adhesion molecule 6 (CEACAM6) and surfactant protein B (SFTPB) improved the specificity and sensitivity in the diagnosis of different lung cancer subtypes. Exosomal TP63, KRT5, CEACAM6 and SFTPB mRNAs can thus be used as biomarkers to differentiate between LUSC and LUAD, and may provide a novel strategy for their differential diagnosis and treatment.
Identifiants
pubmed: 33664813
doi: 10.3892/ol.2021.12510
pii: OL-0-0-12510
pmc: PMC7882885
doi:
Types de publication
Journal Article
Langues
eng
Pagination
249Informations de copyright
Copyright: © Cao et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cell Physiol Biochem. 2017;42(4):1684-1700
pubmed: 28743125
Cancer Res. 2005 Nov 15;65(22):10280-8
pubmed: 16288016
Oncogene. 2019 Feb;38(8):1340-1353
pubmed: 30266990
PLoS One. 2014 Mar 27;9(3):e93287
pubmed: 24676354
J Thorac Dis. 2013 Oct;5 Suppl 5:S463-78
pubmed: 24163740
ACS Nano. 2017 Nov 28;11(11):10712-10723
pubmed: 29090896
Adv Healthc Mater. 2019 Mar;8(6):e1801268
pubmed: 30663276
Cell Mol Life Sci. 2019 Dec;76(23):4613-4633
pubmed: 31352532
Lung Cancer. 2018 Feb;116:46-54
pubmed: 29413050
Sci Rep. 2016 Dec 23;6:39557
pubmed: 28008968
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
Ther Adv Med Oncol. 2012 Mar;4(2):43-50
pubmed: 22423263
Nat Rev Mol Cell Biol. 2001 Apr;2(4):285-93
pubmed: 11283726
J Cancer. 2020 Jul 11;11(18):5413-5423
pubmed: 32742488
J Transl Med. 2019 Oct 29;17(1):355
pubmed: 31665020
Oncotarget. 2017 May 3;8(42):71759-71771
pubmed: 29069744
Genes Chromosomes Cancer. 1998 May;22(1):79-82
pubmed: 9591638
PLoS One. 2015 Jun 01;10(6):e0129482
pubmed: 26030778
Cancer Sci. 2018 May;109(5):1701-1709
pubmed: 29573061
Ann Surg. 2005 Mar;241(3):491-6
pubmed: 15729073
South Asian J Cancer. 2019 Oct-Dec;8(4):250-254
pubmed: 31807491
J Biomed Sci. 2015 Jul 09;22:52
pubmed: 26156586
Signal Transduct Target Ther. 2019 Nov 13;4:47
pubmed: 31728212
Am J Physiol. 1981 Oct;241(4):G275-88
pubmed: 7032321
J Med Life. 2018 Jul-Sep;11(3):210-217
pubmed: 30364567
J Extracell Vesicles. 2013 Jun 18;2:
pubmed: 24009892
Am J Pathol. 2003 Nov;163(5):1949-60
pubmed: 14578194
Eur J Immunol. 2007 Mar;37(3):788-97
pubmed: 17304627
BMC Genomics. 2019 Nov 21;20(1):881
pubmed: 31752667
Mol Cancer. 2019 Sep 4;18(1):134
pubmed: 31484581
Curr Opin Cell Biol. 2014 Aug;29:116-25
pubmed: 24959705
J Biochem. 2010 Jan;147(1):35-51
pubmed: 19762341
Cancer Manag Res. 2019 Aug 07;11:7485-7497
pubmed: 31496806
Cell Rep. 2018 Oct 30;25(5):1332-1345.e5
pubmed: 30380422
Biochim Biophys Acta. 2012 Jul;1820(7):940-8
pubmed: 22503788
BMC Genomics. 2018 Jun 5;19(1):435
pubmed: 29866045
Am J Hum Genet. 2009 Jan;84(1):52-9
pubmed: 19100526
Am J Cancer Res. 2018 Jul 01;8(7):1249-1261
pubmed: 30094098
Nat Commun. 2019 Aug 8;10(1):3578
pubmed: 31395880
Cell. 1993 Sep 10;74(5):813-22
pubmed: 8374952
PLoS One. 2020 May 21;15(5):e0233283
pubmed: 32437446
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Biomaterials. 2015 Oct;67:32-41
pubmed: 26204223
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
Aging (Albany NY). 2019 Dec 9;11(23):11170-11185
pubmed: 31816603
Acta Biochim Biophys Sin (Shanghai). 2015 Jul;47(7):557-63
pubmed: 25994008
J Biomed Sci. 2018 Dec 24;25(1):91
pubmed: 30580764
J Biol Chem. 2017 Feb 10;292(6):2411-2421
pubmed: 28057758
Clin Ther. 2014 Jun 1;36(6):830-46
pubmed: 24952934
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820921248
pubmed: 32329414
J Clin Oncol. 2010 Dec 20;28(36):5311-20
pubmed: 21079145
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Biochim Biophys Acta. 2015 May;1852(5):1020-8
pubmed: 25703140
J Biol Chem. 2017 Nov 10;292(45):18565-18576
pubmed: 28972165
Front Med (Lausanne). 2016 Dec 23;3:69
pubmed: 28066769
EMBO Rep. 2017 Oct;18(10):1870
pubmed: 28970373
Biol Res. 2015 Aug 22;48:47
pubmed: 26297502
J Extracell Vesicles. 2019 Jul 22;8(1):1643670
pubmed: 31448068
J Cancer Res Clin Oncol. 1998;124(9):511-6
pubmed: 9808426
J Cancer. 2018 Oct 18;9(22):4139-4149
pubmed: 30519313
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Diagn Cytopathol. 2009 Mar;37(3):178-83
pubmed: 19170169
Curr Treat Options Oncol. 2017 Aug 10;18(9):54
pubmed: 28795312
Cancer Med. 2020 Jan;9(1):259-268
pubmed: 31692299
J Mol Endocrinol. 2002 Aug;29(1):23-39
pubmed: 12200227
Mol Oncol. 2017 Jun;11(6):599-611
pubmed: 28182330
Cancer Microenviron. 2018 Jun;11(1):13-21
pubmed: 29721824
Gene. 2015 Jan 25;555(2):393-402
pubmed: 25447918
Oncotarget. 2018 Jun 26;9(49):29220-29232
pubmed: 30018747
Oncogene. 2018 Oct;37(40):5387-5402
pubmed: 29880877
Metabolomics. 2018 Aug 31;14(9):118
pubmed: 30830374
J Thorac Dis. 2013 Oct;5 Suppl 5:S479-90
pubmed: 24163741
Mol Cancer Res. 2014 Jan;12(1):3-13
pubmed: 24442106